160 Health International Limited Announces Strategic Expansion of AI-Powered “Medical Digital Staff” System

Date: March 11, 2026

Key Highlights

• Deployment of “Medical Digital Staff” System: 160 Health International Limited (“the Company”) is actively rolling out an advanced “Medical Digital Staff” system across medical institutions, leveraging its integrated “Platform + AI Agent + Operation” business model. This system utilizes state-of-the-art AI agents, such as the proprietary OpenClaw, to optimize medical workflows.
• End-to-End Integration of AI Agents: The Company’s AI agents are being systematically embedded throughout the entire patient journey—including pre-consultation, consultation, and post-consultation phases. Key applications include patient management, health education, streamlined operation of high-value health services, automated medical record generation, intelligent medical insurance calculation, and departmental ledger management.
• Significant Internal Efficiency Gains: Internally, the Company has fully integrated AI agents into its own product R&D, content production, and customer service. This has resulted in a reduction of the product iteration cycle by more than 60%, enabling faster deployment and delivery of solutions to medical institutions.
• Security-First Approach: All AI agents, whether used internally or externally, are subject to comprehensive end-to-end security hardening by the in-house technical team. This ensures the safety and reliability of the Company’s systems.
• Ongoing Optimization and Future Plans: The Company has completed the initial deployment of OpenClaw and is actively optimizing its applications. It aims to explore further advanced AI use cases in authentic doctor-patient interactions and healthcare platform operations, targeting long-term value creation for shareholders.

What Shareholders Should Know

• Potential Price Sensitivity: The progressive deployment of a comprehensive AI-driven digital staff platform marks a major technological leap for the Company, potentially enhancing its competitive positioning in the healthcare industry. Accelerated internal efficiency (notably a >60% reduction in product iteration cycles) and faster delivery to medical institutions could translate into tangible revenue growth and improved margins.
• Scalability and Market Expansion: The adoption of multi-agent AI systems across the full medical service cycle is likely to attract interest from more medical institutions, potentially boosting market share and opening new revenue streams.
• Focus on Security: The Company’s emphasis on robust security protocols addresses a critical concern for healthcare technology, potentially reducing operational risk and building trust with institutional partners and regulators.
• Leadership Stability: The Board continues to be led by Chairman, Executive Director, and CEO Mr. LUO Ningzheng, alongside a blend of executive, non-executive, and independent non-executive directors.

Investor Implications

The announcement signals a pivotal shift in 160 Health International Limited’s business operations, with a clear focus on AI-driven transformation. The successful deployment and internal adoption of AI agents position the Company for enhanced growth prospects and operational resilience. Shareholders should monitor upcoming developments closely, as successful scaling and adoption in the broader medical ecosystem could significantly impact the Company’s valuation and share price.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult with professional advisers before making investment decisions. The Company’s plans and strategies are subject to risks and uncertainties that may affect actual outcomes.

View 160 HEALTH Historical chart here